Effectiveness of Dienogest for Treatment of Recurrent Endometriosis: Multicenter Data
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
This study aimed to assess whether dienogest (DNG) is also effective in patients with recurrent endometriosis based on multicenter data of 121 women who were clinically diagnosed as having recurrent endometriosis and treated for more than 24 weeks with DNG (2 mg daily). We evaluated the changes in endometriosis-associated pain scores (visual analog scale [VAS]), serum cancer antigen 125 (CA-125) levels, and endometrioma sizes following DNG medication in these women along with adverse events associated with DNG medication. The mean duration of DNG treatment was 57.80 (24.08) weeks, and during continuation of DNG, the mean VAS score was 5.03 (1.73) at baseline and significantly decreased to 2.46 (1.32) at 24 weeks after taking DNG. In subgroup analysis, the trend of pain-related symptoms was compared between the symptom-only recurrence group and the recurrent endometrioma group. In both groups, the pain scores decreased significantly during the first 24 weeks but remained relatively unchanged thereafter. Moreover, the size of recurrent endometriomas and CA-125 levels also decreased significantly compared to baseline. The mean size of recurrent endometriomas was 3.77 (1.59) cm in diameter and decreased to 2.74 (1.53) cm after 24 weeks of DNG treatment ( P for trend < .001). The mean CA-125 level was 80.04 U/mL at baseline and significantly decreased to 33.11 U/mL after taking DNG for 24 weeks and lasted until 72 weeks ( P for trend = .0288). Overall, 51 (42.15%) patients reporte…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DNG, a 19-nortestosterone derivative, is the most recent progestin available and labelled for endometriosis and according to a number of evidences it substantially improves endometriosis-related pain symptoms in long term treatment [186].”
From Hormonal treatments for endometriosis: The endocrine background (2022) · cites this paper as [186]
Citations
Cites
Revised American Society for Reproductive Medicine classification of endometriosis: 1996
American Society for Reproductive Medicine (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)81391-x · Cited by 3,018
Bulun, S. E. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804690 · Cited by 1,772
DeLoach, L. J., Higgins, M. S., Caplan, A. B., & Stiff, J. L. (1998) · Anesthesia & Analgesia · doi:10.1097/00000539-199801000-00020 · Cited by 722
Increasing the reliability and validity of pain intensity measurement in chronic pain patients
Jensen, M. P., & McFarland, C. A. (1993) · Pain · doi:10.1016/0304-3959(93)90148-i · Cited by 720
A Unified Approach to Mixed Linear Models
McLean, R. A., Sanders, W. L., & Stroup, W. W. (1991) · The American Statistician · doi:10.1080/00031305.1991.10475767 · Cited by 601 · cited 1×
“To overcome the shortcoming that resulted from a lot of missing values, linear mixed-effects models were chosen for analyses, which is powerful in handling missing values, especially in the context of longitudinal designs.(44) In conclusion, the present retrospective study has shown that DNG is effective in reducing t…”
MethodStrowitzki, T., Marr, J., Gerlinger, C., Faustmann, T., & Seitz, C. (2010) · Human Reproduction · doi:10.1093/humrep/dep469 · Cited by 381 · cited 4×
“42 for the primary outcome.(13) A total of 6 evaluable patients were required to yield a power (1 b) of 90% to demonstrate the efficacy of DNG treatment.”
BackgroundResultInfluentialThe performance of CA-125 measurement in the detection of endometriosis: a meta-analysis
Mol, B. W. J., Bayram, N., Lijmer, J. G., Wiegerinck, M. A. H. M., Bongers, M. Y., van der Veen, F., & Bossuyt, P. M. M. (1998) · Fertility and Sterility · doi:10.1016/s0015-0282(98)00355-0 · Cited by 355
Surgical Treatment of Endometriosis: A 7-Year Follow-up on the Requirement for Further Surgery
Shakiba, K., Bena, J. F., McGill, K. M., Minger, J., & Falcone, T. (2008) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181758ec6 · Cited by 339 · cited 1×
“Without postoperative medication, 45% to 55% of patients who had been treated surgically require further surgery by 5 to 7 years because of recurrent endometriosis.(4) Recent reports suggest that second surgery for recurrent endometrioma is associated with a higher loss of ovarian tissue and ovarian reserve evaluated…”
BackgroundGuo, S.-W. (2009) · Molecular Human Reproduction · doi:10.1093/molehr/gap064 · Cited by 328
Elevated serum concentrations of CA-125 in patients with advanced endometriosis
Barbieri, R. L., Niloff, J. M., Bast, R. C., Schaetzl, E., Kistner, R. W., & Knapp, R. C. (1986) · Fertility and Sterility · doi:10.1016/s0015-0282(16)49333-7 · Cited by 320
Research works printed but not linked: 1
- DeLoach L, Higgins M, Caplan A, Stiff J. The visual analog scale in the immediate postoperative period. Anesth Analg. 1998; 86(1):102–106.
Cited by
Hormonal treatments for endometriosis: The endocrine background
Vannuccini, S., Clemenza, S., Rossi, M., & Petraglia, F. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09666-w · Cited by 336
Use of dienogest in endometriosis: a narrative literature review and expert commentary
Murji, A., Biberoğlu, K., Leng, J., Mueller, M. D., Römer, T., Vignali, M., & Yarmolinskaya, M. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1744120 · Cited by 116
Barra, F., Scala, C., Maggiore, U. L. R., & Ferrero, S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010154 · Cited by 61
“Moreover, in line with previous studies [32,33], the rate of patients experiencing amenorrhea was around 65%, and this status correlated to the almost complete disappearance of menstrual‐related symptoms, and, in particular, dysmenorrhea.”
ResultMuzii, L., Galati, G., Di Tucci, C., Di Feliciantonio, M., Perniola, G., Di Donato, V., Benedetti Panici, P., & Vignali, M. (2020) · Gynecological Endocrinology · doi:10.1080/09513590.2019.1640199 · Cited by 55
“report a decrease in size of 27% after 6months, and of 52% after 14months of dienogest therapy, in a series of 88 patients with ovarian endometriomas [15].”
BackgroundChoi, S. H., Kim, S., Lee, S. W., Won, S., Shim, S. H., Lee, N., Kim, M. K., Jung, Y. W., Seong, S. J., & Kim, M. (2023) · Yonsei Medical Journal · doi:10.3349/ymj.2022.0278 · Cited by 24
Self-citation
Metadata
- Authors
- Lee, J. H., Song, J. Y., Yi, K. W., Lee, S. R., Lee, D.-Y., Shin, J.-H., Cho, S., Seo, S. K., & Kim, S. H.
- Affiliations
- Yonsei University (KR)
- The Catholic University of Korea Uijeongbu St. Mary's Hospital (KR)
- Korea University (KR)
- Ewha Womans University (KR)
- Samsung Medical Center (KR)
- Asan Medical Center (KR)
- Corresponding author
- Seo, Seok Kyo
- Kim, Sung Hoon
- Venue
- Reproductive Sciences
- Published
- 2018-10
- Volume
- 25
- Issue
- 10
- Pages
- 1515-1522
- ISSN
- 1933-7191 (ISSN-L)
- 1933-7205
- OpenAlex
- W2806443010
- Cited by
- 44
- References
- 44
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 8 · 2023: 5 · 2022: 4 · 2021: 5 · 2020: 4 · 2019: 4 · 2018: 2
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by-nc-nd
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Reproductive Sciences (publishedVersion)
- PubMed (publishedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
- Health Sciences › Medicine › Obstetrics and Gynecology › Gynecological conditions and treatments
- Keywords
- dienogest, recurrent endometriosis, endometrioma size, CA125, endometriosis-associated pain, irregular bleeding, adverse events
- MeSH terms
- Adult, Amenorrhea, Endometriosis, Female, Hormone Antagonists, Humans, Nandrolone, Pain, Pain Measurement, Recurrence, Retrospective Studies, Multicenter Studies as Topic, Treatment Outcome, CA-125 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effectiveness of Dienogest for Treatment of Recurrent Endometriosis: Multicenter Data. https://app.cochat.ai/papers/10.1177/1933719118779733
- The paper
- Lee, J. H., Song, J. Y., Yi, K. W., Lee, S. R., Lee, D.-Y., Shin, J.-H., Cho, S., Seo, S. K., & Kim, S. H. (2018). Effectiveness of Dienogest for Treatment of Recurrent Endometriosis: Multicenter Data. Reproductive Sciences. https://doi.org/10.1177/1933719118779733
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.